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S U M M A R Y
Kaposi’s sarcoma and multicentric Castleman Disease are HIV-related disease processes that are
associated with human herpesvirus 8 (HHV-8) infection. The development of multicentric Castleman
disease can often be a manifestation of the immune reconstitution inﬂammatory syndrome
phenomenon and is associated with markedly elevated levels of HHV-8 viremia, as illustrated by
this case.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Human herpesvirus 8 (HHV-8), ﬁrst described in 1994, is a rare
cause of human illness. When associated with HIV infection, HHV-
8 is the etiologic agent of Kaposi’s sarcoma (KS), multicentric
Castleman disease (MCD), and primary effusion lymphoma. MCD is
a rare systemic lymphoproliferative disorder that, in contrast to
many HIV-related diseases, occurs more frequently with improve-
ment in immune status, suggesting an association with immune
reconstitution inﬂammatory syndrome (IRIS). The case presented
here highlights the relationship between KS, MCD, HHV-8, and
IRIS.
2. Case report
A 30-year-old man, with a history of longstanding AIDS,
presented to hospital with hematochezia, lymphadenopathy,
fever, and 5 kg of unintentional weight loss. The patient had been
diagnosed with HIV 7 years previously. At diagnosis his CD4 count
was 350 cells/mm3 and HIV RNA level was 19 500 copies/mm3. He* Corresponding author. Tel.: +1 202 741 2234; fax: +1 202 741 2241.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).was started on combination antiretroviral therapy (cART) with
darunavir, ritonavir, and emtricitabine/tenofovir, but was poorly
compliant with his antiretrovirals due to losing his health
insurance for a prolonged period of time. He was restarted on
darunavir, ritonavir, and emtricitabine/tenofovir 1 month prior to
his current admission by an outside infectious diseases specialist.
At that time his CD4 count was 34 cells/mm3 and his HIV RNA level
was 22 350 copies/mm3. However he was again poorly compliant
with this regimen.
The patient had been diagnosed with KS 3 weeks previously
after being admitted to hospital with profound anemia. There was
no documentation of lymphadenopathy at that time; his CD4+
count was 26 cells/mm3, HIV RNA level 16 370 copies/mm3, and
creatinine 0.9 mg/dl. As part of the evaluation for his anemia, he
underwent an esophagogastroduodenoscopy, which revealed
multiple polypoid lesions in the stomach and duodenum, as well
as extensive erythema and subepithelial hemorrhage in the body
and antrum. Histology was consistent with KS. On discharge he
was instructed to continue his current cART and follow up with his
primary HIV provider.
On hiscurrent admission he was febrile to 38.2 8C withotherwise
stable vital signs. Examination revealed ﬁrm and bulky cervical,
supraclavicular, axillary, and inguinal lymphadenopathy. Blood
work revealed anemia (hemoglobin 5.7 g/dl), thrombocytopeniaciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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(creatinine 1.8 mg/dl). Over the preceding 3 weeks his CD4+ count
had risen to 40 cells/mm3 and HIV RNA level had decreased to
1080 copies/mm3.
Empiric broad-spectrum antibiotics were stopped after 48 h
when his blood cultures remained sterile. Over the next several
days his creatinine rose to 3.7 mg/dl. Emtricitabine/tenofovir was
replaced with dolutegravir/abacavir. He remained febrile with
fevers as high as 39.5 8C. A chest, abdomen, and pelvis computed
tomography scan showed bilateral pleural effusions, scattered
ground glass attenuation in the lungs, and diffuse lymphadenopa-
thy. Thoracentesis was performed and was consistent with an
exudative effusion. Excisional biopsy of a left axillary lymph node
was performed. Pathology showed signiﬁcant disruption of the
nodal architecture, concentric streaming of the mantle zone of the
follicles, irregularly shaped germinal centers with penetrating
hyalinized blood vessels, and expansion of the inter-follicular area
with prominent blood vessels and plasma cells consistent with
MCD (Figure 1a, b). Scattered plasmablasts surrounding follicles
that stained positive for HHV-8 and negative for Epstein–Barr virus
were noted (Figure 1c, d). His plasma HHV-8 concentration was
markedly elevated at >10 000 000 copies/ml, but no pleural ﬂuid
was sent for HHV-8 PCR.Figure 1. Photomicrographs H&E stain (a–c) and anti HHV-8 immunohistochemical stain
the nodal architecture (magniﬁcation, 20). b, Hyalinized vessels penetrating to the germ
plasmablasts in the interfollicular tissue (magniﬁcation, 400). d, Foci of HHV-8 positiThe patient’s respiratory status continued to decline and he was
transferred to the intensive care unit where he was started
empirically on vancomycin and meropenem for possible hospital-
acquired pneumonia. He required intubation, vasopressor support,
and continuous renal replacement therapy for his worsening renal
function. A bronchoscopy was performed and bacterial and
mycobacterial cultures were negative. Cytology was negative for
Pneumocystis jirovecii. Bone marrow examination revealed a
polyclonal plasmacytosis of 20–40%, but no evidence of lymphoma.
Intravenous rituximab and doxorubicin were started and the
patient’s clinical status improved dramatically. He was extubated
after 5 days and was given a second cycle of chemotherapy 4 weeks
later. He was discharged on hemodialysis 6 weeks after admission
and received two more cycles of chemotherapy as an outpatient.
Unfortunately he developed sepsis 2 months after discharge and
died at an outside hospital. No follow-up HHV-8 level was sent as
an outpatient.
3. Discussion
Castleman disease is a rare lymphoproliferative disorder that
may present in two forms: unicentric Castleman disease (UCD),
which is most commonly seen in HIV-negative individuals, and (d). a, Low power image of the lymph node shows there is signiﬁcant disruption of
inal center (magniﬁcation, 400). c, Plasma cells with occasional small clusters of
ve spindle cells forming clusters (magniﬁcation, 400).
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HIV-infected patients. Patients with UCD typically have localized
lymph node enlargement with minimal symptoms. In contrast,
patients with MCD usually have involvement of multiple lymph
nodes and systemic symptoms including fevers, night sweats,
weight loss, and ﬂuid retention. Laboratory abnormalities include
anemia, thrombocytopenia, hypergammaglobulinemia, elevated
inﬂammatory markers, and increased proinﬂammatory cytokines
such as interleukin (IL)-6 and IL-10.1 The diagnosis is established
by histopathological examination of lymph nodes. There are two
histopathological forms that have been recognized. The hyaline
vascular form of the disease reveals regressing or atrophic
germinal centers with lymphocyte depletion, whereas the plasma
cell form of the disease is characterized by hyperplastic germinal
centers.1
MCD is one of three HHV-8-related lymphoproliferative
disorders that are associated with HIV infection. Besides MCD,
both KS and primary effusion lymphoma have been linked to HHV-
8 infection. Patients with KS tend to have lower CD4+ counts and
may experience improvement and occasionally resolution of
lesions with the initiation of antiretroviral therapy alone. In
contrast, HIV-associated MCD presents at any CD4+ count and the
clinical course of the disease does not seem to be affected by the
initiation of cART.2 Indeed, the reported incidence of MCD has
increased since the introduction of cART. A study comparing the
incidence of MCD in the pre-cART (1983–1996), early-cART (1997–
2001), and late-cART (2002–2007) eras showed a statistically
signiﬁcant increase in the incidence of MCD over these periods,
while there was a marked decline in reported KS cases.2
Furthermore, while HIV-related immunosuppression has been
associated with the development of KS, this has not been the case
for MCD. Indeed, individuals on cART with suppressed HIV viremia
are at greater risk of developing MCD. It is suggested that this latter
group is more likely to be able to mount a stronger, albeit
dysregulated, immune response to HHV-8, resulting in the
subsequent intense activation of serum cytokines reﬂected in
the elevated concentrations of inﬂammatory markers and systemic
symptoms seen in patients with MCD.2
HHV-8 is detected in all HIV-associated MCD cases and most
HIV-negative cases.3 Elevated serum HHV-8 viremia is strongly
correlated with HIV-associated MCD, being detectable in 83–100%
of HIV-associated MCD patients,2,4–6 while in only 36–72% of
patients with HIV-associated KS.2,6 The level of HHV-8 viremia is
also substantially higher in patients with MCD compared to KS,
reﬂecting the lytic replication of HHV-8 in MCD versus the more
common latent replication in KS.7 In one study, the median HHV-8
viral load was 43 500 copies/ml in 11 MCD patients, whereas the
median viral load for 25 patients with KS was 320 copies/ml.6
Using a threshold of 1000 copies/ml, Sayer et al. were able to
discriminate between MCD and KS with a speciﬁcity of 94.7% and a
negative predictive value of 97.3%.6 Therefore plasma HHV-8 levels
are an important biomarker to support the diagnosis of MCD and
can be used to monitor the response to therapy1 and to predict the
risk of disease relapse.4
The fact that the incidence of HIV-associated MCD increases
with improving immune status suggests that the development of
this disorder may be a manifestation of IRIS, the paradoxical
inﬂammatory response to subclinical infections following the
initiation of cART. The ﬁrst reported case of MCD-IRIS was in 1999,8
and although the frequency is not known, it is thought to be very
rare. The inﬂammatory response can be severe and occasionally
fatal in HIV-positive patients with known KS who develop MCD-
IRIS after the initiation of cART.8The low baseline CD4+ count, rapid decline in HIV viral load,
and co-infection with HHV-8-related visceral KS were signiﬁcant
risk factors for the present patient developing MCD-IRIS. A report
of three HIV-positive patients who developed MCD-IRIS between
3 and 8 months after the initiation of cART documented markedly
elevated HHV-8 viral loads, ranging from 7.7 to 13.3  106 copies/
ml.5 The present patient’s very high HHV-8 viral load of >10  106
copies/ml provides further support that this case of MCD was an
IRIS phenomenon. The exact mechanism by which the improved
immunity due to cART causes such markedly elevated HHV-8 viral
loads is not understood, although it is most likely due to
accelerated viral lytic replication.
A newly described syndrome of KS herpesvirus-associated
inﬂammatory cytokine syndrome (KICS) – has been documented in
patients with KS and similarly severe systemic inﬂammatory
symptoms. These patients have elevated cytokine levels as are seen
in patients with KS-associated MCD but with no pathological
evidence of MCD.9 The reported mortality rates in these patients
range from 50% to 60%.9,10 Plasma levels of viral IL-6, human IL-6
IL-10 , and KS viremia were signiﬁcantly higher than those found in
HIV-positive patients with KS alone and were comparable to those
seen in HIV-positive patients with MCD. However the median
plasma HHV-8 level in patients with KICS was 81 968 copies/ml
(range 0 to 3 987 997), which was substantially lower than in the
case of the patient presented herein and other reported cases of
MCD-IRIS.
In summary, the pathogenesis of both KS and MCD in HIV-
infected patients is clearly related to HHV-8. However, in the case
of KS, the pathogenesis is clearly linked to the degree of
immunosuppression, whereas in the case of MCD, the pathogene-
sis involves a more complex interaction between HIV-mediated
immunosuppression, antiviral-mediated improvement in host
immune status, and the development of an inﬂammatory response
to HHV-8 infection.
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